Invited review: Drug development for tauopathies

Several compounds targeting tauopathies are currently in clinical development, including small molecules and active vaccines.

• Tau undergoes various post-translational modifications that may affect its aggregation and disease progression.
• Manipulating the extent of these modifications could influence tau-related pathogenesis.
• Enzymes involved in tau modifications may serve as potential targets for drug interventions.
• Modulating tau expression levels is a promising therapeutic strategy.
• The newly identified prion-like spreading of tau between cells may lead to novel drug development pathways.
• There is a need for clinical biomarkers, especially PET imaging, to facilitate drug development.

AI simplified